

18 October 2017

ASX ANNOUNCEMENT

Penthrox approved in Mexico

Medical Developments International Limited (ASX: MVP) is delighted to announce it has received regulatory approval for the sale of Penthrox in Mexico. The Mexican Federal Commission for the Protection against Sanitary Risk ("COFEPRIS") has approved Penthrox for use in patients with moderate to severe Trauma pain **and** for the relief of pain in patients who require analgesia for Surgical Procedures.

Mexico is a country of 127 million people and it is estimated that 37 million patients receive some sort of medical consultation each year. Many of these are treated for trauma and many require analgesia for surgical procedures.

MVP CEO, Mr. John Sharman, said: "We have been waiting on the Mexican authorities to complete the approval process for 2 years. Now that it has arrived we are delighted that we can begin to sell product in Mexico; a key market in Latin America."

Mr. Sharman, said: "Importantly, Penthrox has been approved for use in moderate to severe pain Trauma cases **and** Surgical procedures requiring analgesia. While it is generally accepted the standard of care for trauma victims in Mexico is not the same as in the developed western world, the market opportunity is large. Our partner, Probiomed, estimate that in time Penthrox could sell 800,000 doses per annum in the Trauma pain hospital setting. The numbers of doses that may be used for Surgical procedures is harder to estimate, but anecdotally it is possible this part of the market could be larger than for Trauma."

Enquiries:

John Sharman
Chief Executive Officer
Medical Developments International Ltd
03 9547 1888

David Williams
Chairman
Medical Developments International Ltd
0414 383 593



About Probiomed

Probiomed is a Mexican company focused on the development, manufacture and marketing of biotechnology and pharmaceutical products for human health. It has more than 1200 employees and annual revenues of more than \$100m USD. It services hospitals and emergency departments in Mexico. PROBIOMED has a wide portfolio of pharmaceuticals and recombinant proteins, covering various medical specialties such as Family Medicine, Internal Medicine, Endocrinology, Cardiology, Neurology, Psychiatry, Otorhinolaryngology, Gynecology, Traumatology, Nephrology, Oncology and Hematology.

About Pentrox

Penthrox is a non-opioid, non-addictive, inhaled analgesic indicated in Australia for pain relief by self-administration in patients with trauma and those requiring analgesia for surgical procedures. Penthrox has been used for more than 40 years in Australia and is now sold into 16 countries with circa 6.0 million units sold. There is growing interest in Penthrox being used in patients undergoing investigatory procedures, as well as operational procedures such as colonoscopy.

About Medical Developments International Ltd

MVP is an Australian company delivering emergency medical solutions dedicated to improving patient outcomes. MVP is a leader in emergency pain relief and respiratory products. The Company manufactures Penthrox®, an analgesic product. It is used in Australian Hospitals including Emergency Departments, Australian Ambulance Services, the Australian Defense Forces, Sports Medicine and for analgesia during short surgical procedures such as Dental and Cosmetic surgery. MVP is expanding internationally and manufactures a range of world-leading Asthma respiratory devices.